Rabbit Anti-Phospho-PPAR Gamma (ser273) antibody

Home > Product > Antibody > Rabbit Anti-Phospho-PPAR Gamma (ser273) antibody

Phospho-PPAR Gamma(ser273); P-PPAR Gamma (Phospho-ser273); GLM1; CIMT1; NR1C3; PPARG; PPARG1; PPARG2; PPARG5; PPARgamma; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; Peroxisome pr

Cat:

SL4888R

Species Reactivity：

Human,Mouse,(predicted: Rat,Chicken,Pig,Cow,Rabbit,Sheep,)

Immunogen：

KLH conjugated synthesised phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser273:DK(p-S)PF

Format：

Liquid

Storage instructions：

Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Concentration：

1mg/ml

Clonality：

Polyclonal

Isotype：

IgG

Applications：

WB=1:500-2000ELISA=1:5000-10000IHC-P=1:100-500IHC-F=1:100-500ICC=1:100IF=1:100-500（Paraffin sections need to do antigen repair）not yet tested in other applications.optimal dilutions/concentrations should be determined by the end user.

Host：

Rabbit

Product Overview：

Sample: Lane 1: A431 (Human) Cell Lysate at 30 ug Lane 2: Adipocyte (Mouse) Lysate at 40 ug Lane 3: Lung (Mouse) Lysate at 40 ug Primary: Anti-Phospho-PPAR Gamma (ser273) (SL4888R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 58’51 kD Observed band size: 51 kD Sample: A549 Cell (Human) Lysate at 30 ugPrimary: Anti-Phospho-PPAR Gamma (ser273) (SL 4888R) at 1/300 dilutionSecondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilutionPredicted band size: 57 kDObserved band size: 57 kDSample: HepG2 Cell (Human) Lysate at 30 ugPrimary: Anti-p-PPAR Gamma (ser273) (SL4888R)at 1/300 dilutionSecondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilutionPredicted band size: 57kDObserved band size: 55kDSample: Placenta (Mouse) Lysate at 40 ugPrimary: Anti-Phospho-PPAR Gamma (ser273) (SL4888R) at 1/300 dilutionSecondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilutionPredicted band size: 57 kDObserved band size: 57 kDTissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,SLC0005) at 37℃ for 20 min; Incubation: Anti-Phospho-PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated(SL4888R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(SLC0010) stainingTissue/cell: human gastric carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,SLC0005) at 37℃ for 20 min; Incubation: Anti-Phospho-PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated(SL4888R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(SLC0010) stainingTissue/cell: A549 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, SLC0005) at 37°C for 20 min; Antibody incubation with (Phospho-PPAR Gamma (ser273)) polyclonal Antibody, Unconjugated (SL4888R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.Blank control: A431. Primary Antibody (green line): Rabbit Anti-Phospho-PPAR Gamma (ser273) antibody (SL4888R) Dilution: 1μg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-AF647Dilution: 1μg /test. ProtocolThe cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at-20℃. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed. phosphopeptide non phosphopeptide

prev next

Unit:

Price: $256.00

Product PDFs

Datasheet: Down Datasheet

Other Information
Citations
Protein Attributes
Feedback Wall

This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

Function:
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.

Subunit:
Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with DNTTIP2, MAP2K1/MEK1, PRMT2 and TGFB1I1. Interacts with PDPK1. Interacts with ASXL1 AND ASXL2.

Subcellular Location:
Nucleus. Cytoplasm.

Tissue Specificity:
Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

DISEASE:
Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Similarity:
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

SWISS:
P37231

Gene ID:
5468

Database links:

Entrez Gene: 5468 Human

Entrez Gene: 19016 Mouse

Entrez Gene: 25664 Rat

SwissProt: P37231 Human

SwissProt: P37238 Mouse

SwissProt: O88275 Rat

Unigene: 162646 Human

Unigene: 3020 Mouse

Unigene: 23443 Rat

Picture

Sample:
A549 Cell (Human) Lysate at 30 ug
Primary: Anti-Phospho-PPAR Gamma (ser273) (SL 4888R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 57 kD
Observed band size: 57 kD

Sample: HepG2 Cell (Human) Lysate at 30 ug
Primary: Anti-p-PPAR Gamma (ser273) (SL4888R)at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 57kD
Observed band size: 55kD

Sample: Placenta (Mouse) Lysate at 40 ug
Primary: Anti-Phospho-PPAR Gamma (ser273) (SL4888R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 57 kD
Observed band size: 57 kD

Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,SLC0005) at 37℃ for 20 min;
Incubation: Anti-Phospho-PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated(SL4888R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(SLC0010) staining

Tissue/cell: human gastric carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,SLC0005) at 37℃ for 20 min;
Incubation: Anti-Phospho-PPAR Gamma(ser273) Polyclonal Antibody, Unconjugated(SL4888R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(SLC0010) staining

Tissue/cell: A549 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, SLC0005) at 37°C for 20 min; Antibody incubation with (Phospho-PPAR Gamma (ser273)) polyclonal Antibody, Unconjugated (SL4888R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.

Blank control: A431.
Primary Antibody (green line): Rabbit Anti-Phospho-PPAR Gamma (ser273) antibody (SL4888R)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-AF647
Dilution: 1μg /test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at-20℃. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

phosphopeptide non phosphopeptide

Product Feedback Wall

Specific References (29) | SL4888R has been referenced in 29 publications.

[IF=7.658] Lei Ma. et al. Identification of the anti-fungal drug fenticonazole nitrate as a novel PPARγ-modulating ligand with good therapeutic index: Structure-based screening and biological validation. Pharmacol Res. 2021 Nov;173:105860 WB ; Mouse.

PubMed:34461220

[IF=5.458] Claire Bryant. et al. Selective Modulator of Nuclear Receptor PPARγ with Reduced Adipogenic Potential Ameliorates Experimental Nephrotic Syndrome. Iscience. 2022 Feb;:104001 WB ; Rat.

PubMed:10.1016/j.isci.2022.104001

[IF=1.88] Shihe Zhang. et al. Astragalus polysaccharide regulates brown adipocytes differentiation by miR-6911 targeting Prdm16. 2021 Nov 05 WB ; Mouse.

PubMed:34738642

[IF=2.406] Wang, Xu. et al. Modulatory effect of euxanthone in liver cancer-bearing obese mice: crosstalk between PPARγ and TIMP3 signalling axes. 3 Biotech. 2021 Nov;11(11):1-7 IHC ; Mice.

PubMed:34745815

[IF=2.1] Qiankun Quan. et al. Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease. Mol Med Rep. 2020 Oct;22(4):3277-3288 WB ; Rat.

PubMed:32945455

[IF=5.116] Pengyu Hong. et al. Therapeutic potential of small extracellular vesicles derived from lipoma tissue in adipose tissue regeneration—an in vitro and in vivo study. Stem Cell Res Ther. 2021 Dec;12(1):1-13 IHC ; Human.

PubMed:33789709

[IF=4.171] Yingying Tian. et al. Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance via activation of PPARα/γ in mice. Food Funct. 2020 Sep;11(9):8248-8258 WB ; Mouse.

PubMed:32966473

[IF=4.966] Ye Zhanget al. Thymopentin improves the survival of septic mice by promoting the production of 15‐deoxy‐prostaglandin J2 and activating the PPARγ signaling pathway. FASEB J . 2020 Sep;34(9):11772-11785. WB ; mouse.

PubMed:32652815

[IF=6.133] Huan Y et al. A novel specific PPARγ modulator YR4‐42 ameliorates hyperglycemia and dyslipidemia and hepatic steatosis in diet‐induced obese mice. Diabetes Obes Metab. 2019 Jul 31. WB ; Mouse.

PubMed:31364797

[IF=1.632] Liu Y et al. Isolation and characterization of ovine monocyte-derived macrophages from peripheral blood.(2018)Vet Immunol Immunopathol. Nov;205:83-92. IF ; Sheep.

PubMed:30459005

[IF=3.386] Choung S et al. Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice.PPAR Res. 2018 Jun 13;2018:4292509. WB ; Mouse.

PubMed:30008738

[IF=0] Yuan, Hai-Feng, et al. "Expression of p-PPARγ in the aging thoracic aorta of spontaneously hypertensive rat and inhibitory effect of rosiglitazone." Asian Pacific Journal of Tropical Biomedicine 4.12 (2014): 977-981. IHSLCP ; Rat.

PubMed:10.1596/apjtb.4.201414b416

[IF=4.26] Maganti, Aarthi V., et al. "Peroxisome Proliferator-Activated Receptor-γ Activation Augments the β Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-Obese Diabetic Mice."Journal of Biological Chemistry (2016): jbc-M116. WB ; Mouse.

PubMed:27613867

[IF=4.26] Stechschulte, Lance A., et al. "Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ and RUNX2." Journal of Biological Chemistry (2016). WB ; Mouse.

PubMed:27687725

[IF=3.86] Liu, Lei, et al. "Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats." Molecular and Cellular Endocrinology (2016). WB ; Rat.

PubMed:27916883

[IF=3.23] Sarr, Ousseynou, et al. "Low birth weight male guinea pig offspring display increased visceral adiposity in early adulthood." PloS one 9.6 (2014): e98433. WB ; Guinea Pig.

PubMed:24926663

[IF=5.58] Agrawal, S., et al. "Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome." Scientific Reports 6 (2016): 24392. IHSLCP ; Rat.

PubMed:27142691

[IF=1.29] Pandurangan, Muthuraman, Jeongeun Park, and Eunjung Kim. "Aspartame downregulates 3T3-L1 differentiation." In Vitro Cellular & Developmental Biology-Animal (2014): 1-7. WB ; Mouse.

PubMed:24961835

[IF=2.233] Kiyoko Maruyama. et al. Indomethacin, a non-steroidal anti-inflammatory drug, induces skin dryness via PPARγ in mice. 2021 Oct 30 WB ; Mouse.

PubMed:34719578

[IF=7.103] Hou et al. CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss. (2018) Genes.Dis. 5:290-299 WB ; Mouse.

PubMed:3064193

[IF=7.422] Dan Wu. et al. A Novel Peroxisome Proliferator-Activated Receptor Gamma Ligand Improves Insulin Sensitivity and Promotes Browning of White Adipose Tissue in Obese Mice. Mol Metab. 2021 Oct;:101363 WB ; Mouse.

PubMed:34710641

[IF=5.059] Stephanie Kimet al. Triphenyl phosphate is a selective PPARγ modulator that does not induce brite adipogenesis in vitro and in vivo. Arch Toxicol . 2020 Sep;94(9):3087-3103. WB ; mouse.

PubMed:32683515

[IF=1.54] Zhang Y et al. WSF-7 Inhibits Obesity-Mediated PPARγ Phosphorylation and Improves Insulin Sensitivity in 3T3-L1 Adipocytes. Biol Pharm Bull. 2020;43(3):526-532. WB ; mouse.

PubMed:32115511

[IF=7.199] Zhang C et al. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPARγ-CD36 Pathway. Diabetes. 2019 Jul 10. pii: db181055. WB ; Mouse.

PubMed:31292134

[IF=3.514] Li B et al. Resistin up-regulates LPL expression through the PPARγ-dependent PI3K/AKT signaling pathway impacting lipid accumulation in RAW264. 7 macrophages.Cytokine. 2019 Jul;119:168-174. WB ; Mouse.

PubMed:30925325

[IF=4.5] Liu, Lei, et al. "Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down‐regulation of phosphorylation of PPARγ in 3T3‐L1 cells." Journal of Cellular and Molecular Medicine (2017). WB ; Mouse.

PubMed:29160030

[IF=4.26] Alla, Joshua Abd, et al. "Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice." Journal of Biological Chemistry 291.6 (2016): 2583-2600. WB ; Mouse.

PubMed:26670611

[IF=5.08] Liu, Chang, et al. "Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis." Scientific Reports 5 (2015). WB ; Mouse.

PubMed:25827822

[IF=3.73] Kolli, Vipula, et al. "Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass." PLOS ONE 9.5 (2014): e96323. WB ; Mouse.

PubMed:24810249